• Publications
  • Influence
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanizedExpand
  • 312
  • 12
  • PDF
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
BACKGROUND Several questions arise concerning the use of the anti-CD25 antibody daclizumab to treat multiple sclerosis (MS). OBJECTIVES To answer the following 3 questions related to the efficacyExpand
  • 164
  • 10
Using Peripheral Blood Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke: A Pilot Investigation
Background—Direct brain biopsy is rarely indicated during acute stroke. This study uses peripheral blood mononuclear cells (PBMCs) to determine whether a systemic gene expression profile could beExpand
  • 186
  • 7
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.
OBJECTIVE Maintenance therapy with anti-CD25 antibody has emerged as a potentially useful treatment for multiple sclerosis (MS). Constitutive CD25 expression on CD4+CD25+ regulatory T cells (Treg)Expand
  • 89
  • 6
  • PDF
Intrathecal effects of daclizumab treatment of multiple sclerosis
Objectives: We previously reported that daclizumab, a humanized monoclonal antibody against CD25, reduced contrast-enhancing lesions (CEL) in patients with multiple sclerosis (MS) who were suboptimalExpand
  • 76
  • 5
Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His
Objective: To describe the clinical, radiologic, and pathologic findings of a kindred with oculoleptomeningeal amyloidosis and a newly associated transthyretin mutation. Background: TransthyretinExpand
  • 66
  • 3
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS
Background:Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potentialExpand
  • 50
  • 3
MS, MRI, and the 2010 McDonald criteria
Since the first development of diagnostic criteria for multiple sclerosis (MS), there have been regular revisions of disease definitions and diagnostic thresholds aimed at improving specificity whileExpand
  • 26
  • 2
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis
Rolipram, a prototypic phosphodiesterase-4 inhibitor, is highly effective in suppressing Th1 autoimmunity in multiple animal models, including experimental autoimmune encephalomyelitis. In addition,Expand
  • 29
  • 2
Future immunotherapies in multiple sclerosis.
Immunotherapy of multiple sclerosis (MS) will continue to benefit from an increasing understanding of this disease. This knowledge results in newly defined targets for novel therapies. In thisExpand
  • 17
  • 1
  • PDF